Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia - Aix-Marseille Université Access content directly
Journal Articles Blood Cancer Journal Year : 2015

Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia

Abstract

Tyrosine kinase inhibitor (TKI)-based targeted therapy has significantly modified the outcome for patients with chronic myeloid leukemia (CML) in chronic phase. However, resistance remains a major concern in blastic phase of CML and in Philadelphia chromosome positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). Second- and third-generation TKIs have been developed to overcome resistance to first generation drugs, but selecting the appropriate drug has become a challenge. Various tests are available to determine a patient’s disease status in CML including the mechanisms of resistance when involved, but clinical experience is limited in ALL, especially those with poorly defined ABL1 rearrangements. Here, we report a case of ALL associated with a t(1;9)(q24;q34) RCSD1-ABL1 rearrangement. We show how ex vivo drug response profiling (DRP) may help choose among various therapeutic options.

Domains

Cancer
Fichier principal
Vignette du fichier
bcj201513a (1).pdf (597.71 Ko) Télécharger le fichier
bcj201513a.pdf (597.71 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

hal-01218497 , version 1 (21-10-2015)

Identifiers

Cite

Y Collette, Thomas Prébet, A. Goubard, José Adelaïde, R Castellano, et al.. Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. Blood Cancer Journal, 2015, 5 (e292), ⟨10.1038/bcj.2015.13⟩. ⟨hal-01218497⟩
59 View
203 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More